Literature DB >> 16544950

Oxidative activation of thiacetazone by the Mycobacterium tuberculosis flavin monooxygenase EtaA and human FMO1 and FMO3.

Lian Qian1, Paul R Ortiz de Montellano.   

Abstract

Thiacetazone (TAZ) and ethionamide (ETA) are, respectively, thiourea- and thioamide-containing second line antitubercular prodrugs for which there is an extensive clinical history of cross-resistance in Mycobacterium tuberculosis. EtaA, a recently identified flavin-containing monooxygenase (FMO), is responsible for the oxidative activation of ETA in M. tuberculosis. We report here that EtaA also oxidizes TAZ and identify a sulfinic acid and a carbodiimide as the isolable metabolites. Both of these metabolites are derived from an initial sulfenic acid intermediate. Oxidation of TAZ by EtaA at basic pH favors formation of the carbodiimide, whereas neutral or acidic conditions favor formation of the sulfinic acid. The same metabolites are formed from TAZ by human FMO1 and FMO3. The sulfenic acid and carbodiimide metabolites, but not the sulfinic acid product, readily react with glutathione, the first to regenerate the parent drug and the second to give a glutathione adduct. These reactions may contribute to the antitubercular activity and/or toxicity of TAZ.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16544950      PMCID: PMC2533439          DOI: 10.1021/tx050328b

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  31 in total

Review 1.  A century of tuberculosis.

Authors:  John F Murray
Journal:  Am J Respir Crit Care Med       Date:  2004-06-01       Impact factor: 21.405

2.  [Studies on thiacetazone resistance of tubercle bacilli. 3. Cross resistance between thiacetazone and ethionamide].

Authors:  T Osato; K Tsukagoshi; H Shimizu
Journal:  Kekkaku       Date:  1971-04

3.  Side effects of drugs used to treat tuberculosis.

Authors:  R W Newton
Journal:  Scott Med J       Date:  1975-03       Impact factor: 0.729

Review 4.  Therapeutic drug monitoring in the treatment of tuberculosis.

Authors:  Charles A Peloquin
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 5.  Mycothiol biochemistry.

Authors:  Gerald L Newton; Robert C Fahey
Journal:  Arch Microbiol       Date:  2002-09-03       Impact factor: 2.552

6.  Mycothiol is essential for growth of Mycobacterium tuberculosis Erdman.

Authors:  Dipti Sareen; Gerald L Newton; Robert C Fahey; Nancy A Buchmeier
Journal:  J Bacteriol       Date:  2003-11       Impact factor: 3.490

7.  [Multiple drug resistance: a threat for tuberculosis control].

Authors:  Ernesto Montoro Cardoso
Journal:  Rev Panam Salud Publica       Date:  2004-07

8.  Human flavin-containing monooxygenase form 2 S-oxygenation: sulfenic acid formation from thioureas and oxidation of glutathione.

Authors:  Marilyn C Henderson; Sharon K Krueger; Jan F Stevens; David E Williams
Journal:  Chem Res Toxicol       Date:  2004-05       Impact factor: 3.739

9.  Comparative cytotoxicity of N-substituted N'-(4-imidazole-ethyl)thiourea in precision-cut rat liver slices.

Authors:  Rob C A Onderwater; Jan N M Commandeur; Nico P E Vermeulen
Journal:  Toxicology       Date:  2004-04-15       Impact factor: 4.221

Review 10.  The global situation of MDR-TB.

Authors:  Marcos A Espinal
Journal:  Tuberculosis (Edinb)       Date:  2003       Impact factor: 3.131

View more
  27 in total

Review 1.  The TetR family of regulators.

Authors:  Leslie Cuthbertson; Justin R Nodwell
Journal:  Microbiol Mol Biol Rev       Date:  2013-09       Impact factor: 11.056

2.  Acid stress response of a mycobacterial proteome: insight from a gene ontology analysis.

Authors:  Bryan Ap Roxas; Qingbo Li
Journal:  Int J Clin Exp Med       Date:  2009-11-10

3.  High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv.

Authors:  Subramaniam Ananthan; Ellen R Faaleolea; Robert C Goldman; Judith V Hobrath; Cecil D Kwong; Barbara E Laughon; Joseph A Maddry; Alka Mehta; Lynn Rasmussen; Robert C Reynolds; John A Secrist; Nice Shindo; Dustin N Showe; Melinda I Sosa; William J Suling; E Lucile White
Journal:  Tuberculosis (Edinb)       Date:  2009-09-15       Impact factor: 3.131

4.  Bioactivation of antituberculosis thioamide and thiourea prodrugs by bacterial and mammalian flavin monooxygenases.

Authors:  Clinton R Nishida; Paul R Ortiz de Montellano
Journal:  Chem Biol Interact       Date:  2010-09-21       Impact factor: 5.192

5.  The potentially deleterious functional variant flavin-containing monooxygenase 2*1 is at high frequency throughout sub-Saharan Africa.

Authors:  Krishna R Veeramah; Mark G Thomas; Michael E Weale; David Zeitlyn; Ayele Tarekegn; Endashaw Bekele; Nancy R Mendell; Elizabeth A Shephard; Neil Bradman; Ian R Phillips
Journal:  Pharmacogenet Genomics       Date:  2008-10       Impact factor: 2.089

6.  Isoxyl activation is required for bacteriostatic activity against Mycobacterium tuberculosis.

Authors:  Jana Korduláková; Yves L Janin; Avraham Liav; Nathalie Barilone; Tiago Dos Vultos; Jean Rauzier; Patrick J Brennan; Brigitte Gicquel; Mary Jackson
Journal:  Antimicrob Agents Chemother       Date:  2007-09-04       Impact factor: 5.191

7.  Flavin-containing monooxygenase S-oxygenation of a series of thioureas and thiones.

Authors:  Marilyn C Henderson; Lisbeth K Siddens; Sharon K Krueger; J Fred Stevens; Karen Kedzie; Wenkui K Fang; Todd Heidelbaugh; Phong Nguyen; Ken Chow; Michael Garst; Daniel Gil; David E Williams
Journal:  Toxicol Appl Pharmacol       Date:  2014-04-12       Impact factor: 4.219

8.  Metabolism of the anti-tuberculosis drug ethionamide by mouse and human FMO1, FMO2 and FMO3 and mouse and human lung microsomes.

Authors:  Marilyn C Henderson; Lisbeth K Siddens; Jeffrey T Morré; Sharon K Krueger; David E Williams
Journal:  Toxicol Appl Pharmacol       Date:  2008-10-01       Impact factor: 4.219

9.  Human flavin-containing monooxygenase 2.1 catalyzes oxygenation of the antitubercular drugs thiacetazone and ethionamide.

Authors:  Asvi A Francois; Clinton R Nishida; Paul R Ortiz de Montellano; Ian R Phillips; Elizabeth A Shephard
Journal:  Drug Metab Dispos       Date:  2008-10-23       Impact factor: 3.922

10.  Xanthates: Metabolism by Flavoprotein-Containing Monooxygenases and Antimycobacterial Activity.

Authors:  Stanislav G Yanev; Tsveta D Stoyanova; Violeta V Valcheva; Paul R Ortiz de Montellano
Journal:  Drug Metab Dispos       Date:  2018-05-18       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.